EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

A miR-340/SPP1 axis inhibits the activation and proliferation of hepatic stellate cells by inhibiting the TGF-β1/Smads pathway

Ronghua Zhang, Meimei Wang, Hongjian Lu, Jingyao Wang, Xiangyang Han, Zhiyong Liu, Lin Li, Mingming Li, Xiaoli Tian, Shuang Chen, Guangling Zhang, Yanan Xiong und 1 weitere

Advances in Clinical and Experimental Medicine · 2022

DOI: 10.17219/acem/154996 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Clinical and Experimental Medicine, 2022. Verfasst von Ronghua Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Hebei Key Laboratory for Chronic Diseases, School of Basic Medical Sciences, North China University of Science and Technology, Tangshan, China. Hauptthemen laut MEDLINE: MicroRNAs, Transforming Growth Factor beta1. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsTransforming Growth Factor beta1AnimalsHumansRatsCell ProliferationCollagen Type IHepatic Stellate CellsLiver CirrhosisOsteopontinSmad Proteins

Stichwörter der Autor:innen

TGF-β1 signalinghepatic fibrosishepatic stellate cellsmiR-340-5psecreted phosphoprotein 1

Substanzen

Collagen Type IMicroRNAsMIRN340 microRNA, humanOsteopontinSPP1 protein, humanTransforming Growth Factor beta1Smad Proteins

Autor:innen und Institutionen

  • Hebei Key Laboratory for Chronic Diseases, School of Basic Medical Sciences, North China University of Science and Technology, Tangshan, China.
  • School of Clinical Medicine, North China University of Science and Technology, Tangshan, China.
  • Health Science Center, North China University of Science and Technology, Tangshan, China.
  • Gastroenterology Department, Tangshan Paraplegia Sanatorium, China.
  • Tianjin Key Laboratory of Early Druggability Evaluation of Innovative Drugs, Tianjin International Joint Academy of Biomedicine, China.
  • The Cancer Institute, Hebei Key Laboratory of Molecular Oncology, Tangshan People's Hospital, China.

Zitieren

APA

Zhang, R., Wang, M., Lu, H., Wang, J., Han, X., Liu, Z., Li, L., Li, M., Tian, X., Chen, S., Zhang, G., Xiong, Y., & Li, J. (2022). A miR-340/SPP1 axis inhibits the activation and proliferation of hepatic stellate cells by inhibiting the TGF-β1/Smads pathway. Advances in Clinical and Experimental Medicine. https://doi.org/10.17219/acem/154996

Vancouver

Zhang R, Wang M, Lu H, Wang J, Han X, Liu Z, et al. A miR-340/SPP1 axis inhibits the activation and proliferation of hepatic stellate cells by inhibiting the TGF-β1/Smads pathway. Advances in Clinical and Experimental Medicine. 2022. doi:10.17219/acem/154996

BibTeX
@article{Zhang2022,
  author = {Zhang, Ronghua and Wang, Meimei and Lu, Hongjian and Wang, Jingyao and Han, Xiangyang and Liu, Zhiyong and Li, Lin and Li, Mingming and Tian, Xiaoli and Chen, Shuang and Zhang, Guangling and Xiong, Yanan and Li, Jingwu},
  title = {A miR-340/SPP1 axis inhibits the activation and proliferation of hepatic stellate cells by inhibiting the TGF-β1/Smads pathway},
  journal = {Advances in Clinical and Experimental Medicine},
  year = {2022},
  doi = {10.17219/acem/154996}
}
Kostenlos starten →